Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of VYNE Therapeutics Inc (NASDAQ: VYNE) was $0.34 for the day, down -1.94% from the previous closing price of $0.35. In other words, the price has decreased by -$1.94 from its previous closing price. On the day, 2.05 million shares were traded. VYNE stock price reached its highest trading level at $0.3649 during the session, while it also had its lowest trading level at $0.3391.
Ratios:
Our analysis of VYNE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.60 and its Current Ratio is at 7.60. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On November 18, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $8.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 15 ’25 when LEPORE PATRICK G bought 15,000 shares for $2.92 per share. The transaction valued at 43,800 led to the insider holds 51,472 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYNE now has a Market Capitalization of 5732726 and an Enterprise Value of -30859576. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.25 while its Price-to-Book (P/B) ratio in mrq is 0.17. Its current Enterprise Value per Revenue stands at -64.831.
Stock Price History:
The Beta on a monthly basis for VYNE is 1.81, which has changed by -0.81202185 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, VYNE has reached a high of $4.30, while it has fallen to a 52-week low of $0.33. The 50-Day Moving Average of the stock is -65.37%, while the 200-Day Moving Average is calculated to be -82.13%.
Shares Statistics:
VYNE traded an average of 1.86M shares per day over the past three months and 2670990 shares per day over the past ten days. Insiders hold about 18.25% of the company’s shares, while institutions hold 53.38% stake in the company. Shares short for VYNE as of 1753920000 were 2090114 with a Short Ratio of 1.12, compared to 1751241600 on 819146. Therefore, it implies a Short% of Shares Outstanding of 2090114 and a Short% of Float of 12.67.
Earnings Estimates
At present, 2.0 analysts are actively evaluating the performance of VYNE Therapeutics Inc (VYNE) in the stock market.The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.12 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.89 and -$0.89 for the fiscal current year, implying an average EPS of -$0.89. EPS for the following year is -$1.1, with 1.0 analysts recommending between -$1.1 and -$1.1.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 1 analysts. It ranges from a high estimate of $100k to a low estimate of $100k. As of the current estimate, VYNE Therapeutics Inc’s year-ago sales were $121kFor the next quarter, 1 analysts are estimating revenue of $100k. There is a high estimate of $100k for the next quarter, whereas the lowest estimate is $100k.
